0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Protection Against Hepatitis A by an Inactivated Vaccine

Bruce L. Innis, MD; Rapin Snitbhan, MD; Prayura Kunasol, MD; Thanom Laorakpongse, MD; Weera Poopatanakool, MD; Christine A. Kozik, MPH; Saroj Suntayakorn, MD; Tithinun Suknuntapong, MA; Assad Safary, MD; Douglas B. Tang, PhD; John W. Boslego, MD
JAMA. 1994;271(17):1328-1334. doi:10.1001/jama.1994.03510410040030.
Text Size: A A A
Published online

Objective.  —To evaluate the safety and efficacy of a new inactivated hepatitis A vaccine.

Design.  —Double-blind randomized controlled trial stratified by community.

Setting.  —Community-based in Thailand.

Study Participants.  —A total of 40119 children, aged 1 to 16 years, attending 148 primary schools: 38 157 (95%) entered surveillance a mean of 138 days after receiving vaccine dose 1; 33 586 (84%) completed the controlled trial of 532 days; and 31 075 (81%) received crossover vaccine and remained under surveillance until day 844.

Intervention.  —Participants received hepatitis A vaccine or control hepatitis B vaccine starting January 7,1991 (doses in months 0,1, and 12), and crossed over to the alternate vaccine 18 months later.

Main Outcome Measure.  —Cases of hepatitis A (symptoms, alanine aminotransferase levels of 45 U/L or higher, and IgM to hepatitis A virus) were identified by evaluating school absences of 2 or more days.

Results.  —There were no serious adverse reactions despite administration of more than 109000 doses of hepatitis A vaccine. Among initially seronegative recipients of two doses of hepatitis A vaccine, the proportion with 20 mlU/mL or more of antibody to hepatitis A virus before and 5 months after a 1-year booster was 94% and 99%, respectively. Of 6976 episodes of illness during the controlled trial, there were 40 cases of hepatitis A; 38 were in the control group. Of the 40 cases, six, all in controls, occurred after the 1-year booster dose. Following two doses of hepatitis A vaccine (days 138 through 386), protective efficacy was 94% (95% confidence interval, 79% to 99%); cumulative efficacy including the postbooster period (days 138 to 532) was 95% (95% confidence interval, 82% to 99%). The two hepatitis A vaccine recipients who had symptomatic infections (257 and 267 days after dose 1) appeared to have been partially protected since their illnesses were brief and associated with only slight increases in alanine aminotransferase.

Conclusions.  —Inactivated hepatitis A vaccine is safe; when administered in two doses, it protects against hepatitis A for at least 1 year.(JAMA. 1994;271:1328-1334)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();